Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.
Combination of CCR5 and CXCR4 inhibitors in therapy of human immunodeficiency virus type 1 infection: in vitro studies of mixed virus infections.
复制标题
CCR5 和 CXCR4 抑制剂联合治疗人类免疫缺陷病毒 1 型感染：混合病毒感染的体外研究。
DOI：
10.1128/jvi.74.19.9328-9332.2000
复制
发表时间：
2000
影响因子：
5.4
通讯作者：
Hirsch,MS
中科院分区：
文献类型：
--
作者：
Rusconi,S;LaSetaCatamancio,S;Citterio,P;Bulgheroni,E;Croce,F;Herrmann,SH;Offord,RE;Galli,M;Hirsch,MS
我们研究了基质衍生因子1β（SDF-1β）衍生物Met-SDF-1β和RANTES修饰形式氨氧基戊烷（AOP）-RANTES的联合抗人类免疫缺陷病毒1型（HIV-1）作用。在95%和99%病毒抑制浓度下单独或组合测试抗病毒剂。使用临床R5和X4 HIV-1分离株。AOP-RANTES抑制R5病毒，但不抑制X4病毒，而Met-SDF-1β具有相反的作用。这些化合物的组合抑制R5和X4病毒的混合感染（95 - 99%），而单一药物的抑制作用较小（32 - 61%）。R5和X4抑制剂的组合是有前途的，值得进一步评估。
We studied the combined anti-human immunodeficiency virus type 1 (HIV-1) effects of a derivative of stroma-derived factor 1β (SDF-1β), Met-SDF-1β, and a modified form of RANTES, aminooxypentane (AOP)-RANTES. The antiviral agents were tested singly or in combination at 95 and 99% virus inhibitory concentrations. Clinical R5 and X4 HIV-1 isolates were used. AOP-RANTES inhibited R5 but not X4 viruses, whereas Met-SDF-1β had the opposite effect. Combinations of these compounds inhibited mixed infections with R5 and X4 viruses (95 to 99%), whereas single drugs were less inhibitory (32 to 61%). Combinations of R5 and X4 inhibitors are promising and deserve further evaluation.